AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2697 companies scored · 2026-10-16 run in progress: 25 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-15 run
Companies scored 2697 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.11% Alpha · 30D
Long–short spread +2.04% Strong Buy minus Strong Sell, mean
Median IC 0.20 Spearman · 30D
Rating changes ▲ 522 ▼ 1003 vs the previous run
Cross-section

Distribution of the day's forecasts

30D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

304 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
251 IPSCCentury Therapeutics, Inc. Life Sciences 0.22 $250M Unlock rating and forecasts
252 LABSTANDARD BIOTOOLS INC. Life Sciences -0.02 $247M Unlock rating and forecasts
253 BIOABioAge Labs, Inc. Life Sciences 0.32 $246M Unlock rating and forecasts
254 AMRNAMARIN CORP PLC\UK Life Sciences 0.11 $243M Neutral +0.07% +0.17% ▼ 1
255 LFCRLIFECORE BIOMEDICAL, INC. \DE\ Life Sciences 0.06 $243M Unlock rating and forecasts
256 FATEFATE THERAPEUTICS INC Life Sciences 0.07 $231M Unlock rating and forecasts
257 SABSSAB Biotherapeutics, Inc. Life Sciences 0.28 $227M Neutral -0.01% +0.02% ▼ 1
258 GLSIGreenwich LifeSciences, Inc. Life Sciences 0.12 $226M Unlock rating and forecasts
259 SIGASIGA TECHNOLOGIES INC Life Sciences 0.47 $223M Unlock rating and forecasts
260 NATRNATURES SUNSHINE PRODUCTS INC Life Sciences 0.44 $222M Unlock rating and forecasts
261 IMRXImmuneering Corp Life Sciences 0.28 $221M Unlock rating and forecasts
262 KROSKeros Therapeutics, Inc. Life Sciences 0.25 $219M Neutral +0.04% +0.10% ▼ 1
263 LXEOLexeo Therapeutics, Inc. Life Sciences -0.11 $216M Unlock rating and forecasts
264 ALECAlector, Inc. Life Sciences 0.11 $213M Unlock rating and forecasts
265 PLXProtalix BioTherapeutics, Inc. Life Sciences -0.09 $210M Unlock rating and forecasts
266 NAGENiagen Bioscience, Inc. Life Sciences 0.34 $200M Unlock rating and forecasts
267 AKBAAkebia Therapeutics, Inc. Life Sciences 0.25 $193M Unlock rating and forecasts
268 RNACCartesian Therapeutics, Inc. Life Sciences 0.20 $192M Unlock rating and forecasts
269 ADCTADC Therapeutics SA Life Sciences 0.24 $190M Unlock rating and forecasts
270 CGENCOMPUGEN LTD Life Sciences 0.42 $189M Neutral -0.10% -0.22% ·
271 ACOGAlpha Cognition Inc. Life Sciences 0.28 $188M Unlock rating and forecasts
272 UPBUpstream Bio, Inc. Life Sciences 0.64 $187M Unlock rating and forecasts
273 SIONSionna Therapeutics, Inc. Life Sciences 0.04 $185M Unlock rating and forecasts
274 IVVDInvivyd, Inc. Life Sciences 0.23 $179M Unlock rating and forecasts
275 TRDAEntrada Therapeutics, Inc. Life Sciences 0.20 $177M Unlock rating and forecasts
276 STROSUTRO BIOPHARMA, INC. Life Sciences 0.59 $174M Unlock rating and forecasts
277 ORMPORAMED PHARMACEUTICALS INC. Life Sciences -0.03 $172M Unlock rating and forecasts
278 ZNTLZentalis Pharmaceuticals, Inc. Life Sciences 0.31 $166M Unlock rating and forecasts
279 CHRSCoherus Oncology, Inc. Life Sciences 0.11 $165M Unlock rating and forecasts
280 CMPXCompass Therapeutics, Inc. Life Sciences 0.16 $161M Unlock rating and forecasts
281 PEPGPepGen Inc. Life Sciences -0.02 $161M Unlock rating and forecasts
282 MDWDMediWound Ltd. Life Sciences 0.25 $153M Neutral -0.11% -0.80% ▲ 1
283 NBPNovaBridge Biosciences Life Sciences 0.39 $148M Unlock rating and forecasts
284 MOLNMOLECULAR PARTNERS AG Life Sciences 0.04 $147M Neutral -0.10% +0.14% ·
285 ORGOOrganogenesis Holdings Inc. Life Sciences 0.18 $147M Unlock rating and forecasts
286 TARAProtara Therapeutics, Inc. Life Sciences 0.16 $147M Unlock rating and forecasts
287 NKTXNkarta, Inc. Life Sciences 0.06 $145M Unlock rating and forecasts
288 DERMJourney Medical Corp Life Sciences 0.14 $139M Unlock rating and forecasts
289 ANTXAN2 Therapeutics, Inc. Life Sciences 0.03 $136M Unlock rating and forecasts
290 KRROKorro Bio, Inc. Life Sciences 0.07 $131M Unlock rating and forecasts
291 HUMAHumacyte, Inc. Life Sciences -0.01 $118M Unlock rating and forecasts
292 ENGNenGene Therapeutics Inc. Life Sciences 0.30 $115M Neutral +0.01% +0.06% ·
293 OTLKOutlook Therapeutics, Inc. Life Sciences 0.18 $114M Unlock rating and forecasts
294 ARMPArmata Pharmaceuticals, Inc. Life Sciences 0.24 $112M Unlock rating and forecasts
295 CLLSCellectis S.A. Life Sciences 0.13 $112M Unlock rating and forecasts
296 FHTXFoghorn Therapeutics Inc. Life Sciences 0.12 $112M Unlock rating and forecasts
297 NERVMinerva Neurosciences, Inc. Life Sciences 0.12 $112M Unlock rating and forecasts
298 MISTMilestone Pharmaceuticals Inc. Life Sciences 0.09 $112M Neutral +0.10% +0.22% ▼ 2
299 SPRBSPRUCE BIOSCIENCES, INC. Life Sciences 0.01 $112M Unlock rating and forecasts
300 LENZLENZ Therapeutics, Inc. Life Sciences 0.42 $108M Unlock rating and forecasts
251–300 of 304 Previous Next
Since the previous run

Rating changes

▲ 522▼ 1003
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.